Arrowhead Pharmaceuticals (ARWR) Capital Leases (2011 - 2016)
Arrowhead Pharmaceuticals' (ARWR) quarterly Capital Leases came in at $378862.0 in Q2 2016, down 36.38% YoY from $595516.0 in Q3 2015, and down 12.03% on a QoQ basis from $430665.0 in Q1 2016.
Arrowhead Pharmaceuticals (ARWR) Capital Leases (2011 - 2016) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 6 years of Capital Leases data on file, last reported at $378862.0 in Q2 2016.
- Quarterly Capital Leases fell 36.38% year-over-year to $378862.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $378862.0 (down 36.38% YoY) and the FY2015 annual result came in at $540792.0, down 28.69% from the prior year.
- Capital Leases retreated to $378862.0 in Q2 2016, from $430665.0 in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $1.4 million in Q1 2012 to a low of $378862.0 in Q2 2016.
- A 5-year average of $878776.7 and a median of $838973.0 in 2014 frame the typical range for Capital Leases.
- Annual changes were most pronounced in 2012 — Capital Leases dropped 15.0% — and 2016, when it sank 36.38%.
- Tracing ARWR's Capital Leases over 5 years: stood at $1.2 million in 2012, then decreased by 18.03% to $1.0 million in 2013, then decreased by 29.93% to $705173.0 in 2014, then plunged by 31.1% to $485842.0 in 2015, then dropped by 22.02% to $378862.0 in 2016.
- The last three Capital Leases figures came in at $378862.0 (Q2 2016), $430665.0 (Q1 2016), and $485842.0 (Q4 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 378,862.00 |
| Mar 31, 2016 | 430,665.00 |
| Dec 31, 2015 | 485,842.00 |
| Sep 30, 2015 | 540,792.00 |
| Jun 30, 2015 | 595,516.00 |
| Mar 31, 2015 | 650,014.00 |
| Dec 31, 2014 | 705,173.00 |
| Sep 30, 2014 | 758,340.00 |
| Jun 30, 2014 | 812,169.00 |
| Mar 31, 2014 | 865,777.00 |
| Dec 31, 2013 | 1.01 Mn |
| Sep 30, 2013 | 1.06 Mn |
| Jun 30, 2013 | 1.12 Mn |
| Mar 31, 2013 | 1.17 Mn |
| Dec 31, 2012 | 1.23 Mn |
| Sep 30, 2012 | 1.28 Mn |
| Jun 30, 2012 | 1.34 Mn |
| Mar 31, 2012 | 1.39 Mn |
| Dec 31, 2011 | 1.44 Mn |